[Modified biological behaviour of 99mTc-pertechnetate in man as a result of a preceeding administration of tin (tin effect) (author's transl)].
An increased image of blood-filled spaces (Plexus choriodeus, Sinus transversus) was observed in 99mTc-pertechnetate scintigraphy when it had been preceded by the administration of tin (e.g. of 99mTc-Sn-diphosphonate). We have called this behaviour the "tin effect". In vitro studies demonstrated binding of about 80% of the administered activity in the blood with a biological half-life of about 44 hr and an effective half-life of about 5.3 hr. 95% of the blood activity was bound to red cells and 5% to plasma. This resulted in an increased radiation dose to the bone marrow of about 530 mrad/mCi 99mTc-pertechnetate (following tin). The extent of the tin effect decreased with the length of the interval between tin and 99mTc-pertechnetate administration. Because of the tin effect 99mTc-DTPA or 99mTc-citrate should be used for brain scintigraphy if this has to be performed within the first 5 or 7 days following a bone scintigraphy with a tin-containing radiopharmaceutical. The "tin effect" might be taken advantages of when labelling red cells and imaging vascular spaces.
D001921:Brain / Q000000981:diagnostic imaging; D002831:Choroid Plexus / Q000378:metabolism; D004388:Dura Mater / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D011877:Radionuclide Imaging; D013667:Technetium; D014001:Tin / Q000008:administration & dosage*
D013667:Technetium; D014001:Tin
Verändertes biologisches Verhalten zon 99mTc-Pertechnetat nach vorangegangener Zinngabe ("Zinn-Effekt") am Menschen.